Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
106.06
-7.28 (-6.42%)
At close: Jan 15, 2026, 4:00 PM EST
106.11
+0.05 (0.05%)
Pre-market: Jan 16, 2026, 5:32 AM EST
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 283 employees as of December 31, 2024. The number of employees increased by 57 or 25.22% compared to the previous year.
Employees
283
Change (1Y)
57
Growth (1Y)
25.22%
Revenue / Employee
$616,021
Profits / Employee
-$698,625
Market Cap
7.08B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | 90 | 20 | 28.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RYTM News
- 6 days ago - Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - GlobeNewsWire
- 5 weeks ago - Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster - Seeking Alpha
- 5 weeks ago - Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript - Seeking Alpha
- 5 weeks ago - Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise - Benzinga
- 5 weeks ago - Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome - GlobeNewsWire
- 7 weeks ago - Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 - GlobeNewsWire